QuidelOrtho Corporation $QDEL Holdings Lifted by Gagnon Securities LLC

Gagnon Securities LLC grew its stake in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 29.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 159,177 shares of the company’s stock after acquiring an additional 36,678 shares during the period. Gagnon Securities LLC’s holdings in QuidelOrtho were worth $4,546,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in QuidelOrtho by 1,218.7% during the 1st quarter. Royal Bank of Canada now owns 80,193 shares of the company’s stock worth $2,803,000 after buying an additional 74,112 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in QuidelOrtho by 10.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company’s stock worth $7,987,000 after acquiring an additional 21,968 shares during the period. Focus Partners Wealth boosted its position in QuidelOrtho by 210.9% during the 1st quarter. Focus Partners Wealth now owns 20,454 shares of the company’s stock worth $715,000 after acquiring an additional 13,876 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in QuidelOrtho during the 2nd quarter worth about $1,313,000. Finally, EverSource Wealth Advisors LLC boosted its position in QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock worth $93,000 after acquiring an additional 2,309 shares during the period. 99.00% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on QDEL shares. Zacks Research lowered QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st. Jefferies Financial Group lowered QuidelOrtho from a “buy” rating to a “hold” rating and dropped their target price for the stock from $35.00 to $12.50 in a research report on Thursday, May 7th. UBS Group reaffirmed a “neutral” rating and issued a $12.00 target price on shares of QuidelOrtho in a research report on Thursday, May 7th. Finally, Citigroup dropped their target price on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Three research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, QuidelOrtho presently has a consensus rating of “Reduce” and a consensus price target of $14.88.

QuidelOrtho Trading Up 0.3%

Shares of NASDAQ:QDEL opened at $14.13 on Friday. The company has a market cap of $963.52 million, a P/E ratio of -0.79 and a beta of 0.77. The stock’s 50-day moving average is $13.03 and its 200-day moving average is $21.29. QuidelOrtho Corporation has a 52-week low of $9.92 and a 52-week high of $35.58. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.41). The business had revenue of $619.80 million during the quarter, compared to analyst estimates of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The company’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities research analysts predict that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.